Do oral semaglutides work — and how well?

Step 1: Understanding what oral semaglutide does in the body

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating; it signals fullness to the brain, slows the speed at which food leaves the stomach, and plays a role in regulating blood sugar. Oral semaglutide recreates this signal artificially, keeping it active for far longer than the natural hormone would.

The challenge with giving semaglutide as a tablet has always been absorption. Stomach acid degrades the molecule before it reaches the bloodstream in meaningful quantities. The Wegovy tablet, developed by Novo Nordisk, gets around this by combining semaglutide with an absorption enhancer called SNAC, which protects it through the stomach lining. That co-formulation is what makes an effective oral version possible at all.

Because the tablet needs to absorb through the stomach wall directly, how you take it matters enormously. You swallow it whole first thing in the morning, on a completely empty stomach, with a small amount of plain water, no more than around 120ml. Then you wait at least 30 minutes before eating, drinking anything else, or taking other medicines. Missing that window doesn't just delay a dose; it can meaningfully reduce how much reaches your system. The full picture of how oral semaglutide works covers the absorption mechanism in more detail.

Step 2: What the clinical trial actually found

The OASIS 4 trial enrolled 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes. It ran for 64 weeks, comparing the 25mg tablet against placebo alongside lifestyle changes, and it's the evidence base behind the MHRA's June 2026 approval.

The headline: average weight loss of approximately 13.6% in the semaglutide group, against about 2.4% in the placebo group. Among participants who took their tablet consistently throughout, the figure reached roughly 17%. That 17% figure carries an important caveat, it reflects full adherence in a controlled trial setting, not a general-population average. Quote both numbers together and it tells an honest story; quote only the higher one without context and it misleads.

The most commonly reported side effects were gastrointestinal: nausea, vomiting, diarrhoea and constipation featured in about 74% of the semaglutide group, compared with around 42% of the placebo group. Most were mild to moderate and settled as the body adjusted, particularly after dose changes. You can read more about semaglutide tablets including what to expect during the starting weeks.

For context, the MHRA's approval and the trial design are documented in the MHRA's semaglutide approval announcements on GOV.UK.

Step 3: How this compares with the injection, and who it might suit better

The Wegovy injection at its 2.4mg weekly dose produced around 15% average weight loss in the STEP 1 trial over 68 weeks, as published in the New England Journal of Medicine. The tablet's 13.6% average sits slightly below that, though the trials differ in design, duration and population, so a head-to-head comparison should be read carefully rather than as a definitive ranking.

Where the tablet has a practical edge is convenience. No needles, no sharps disposal, no refrigerator required. For people who travel frequently, work irregular hours, or are simply more comfortable with a daily tablet than a weekly injection, those factors are real. One thing worth knowing: the tablet must be taken in a very specific way to work properly, so the discipline around the morning routine is non-negotiable.

The licensed eligibility criteria are: adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, or prediabetes. Lower thresholds apply for certain ethnic backgrounds under UK clinical guidance. Pregnancy, breastfeeding, and trying to conceive are all situations where this medicine is not recommended; the same applies to anyone under 18. A prescriber reviews the whole picture (your health history, current medicines, and circumstances) before a prescription is issued. The options for getting semaglutide tablets in the UK are covered separately, including what to expect from the assessment process.

Step 4: What the NHS says, and the private route

The Wegovy tablet is not currently available on the NHS. The MHRA approved it in June 2026, but a NICE appraisal would be required before NHS commissioning, that process typically takes months to years. For now, private prescription is the only route.

That means a legitimate consultation with a registered prescriber, clinical assessment, and a prescription, not a tablet ordered without any clinical check. The evidence on oral semaglutides for weight loss shows they can be genuinely effective; the question of whether they're right for you is one a prescriber has to answer. You can also get a broader sense of weight management treatment options before deciding anything.

At nume, our prescribers review every consultation the same day it's submitted, a real clinician, not automated software, reads your answers. If treatment is appropriate and you order before 12pm on a working day, it's dispatched that afternoon. There's no fridge to worry about with the tablet, which makes the whole thing a bit simpler when it arrives. If you'd like to understand the cost side before going further, our treatment and pricing page sets out exactly what's included.

Our clinical team's approach is described on the clinical team page, and the NHS semaglutide page is worth reading for a patient-level overview of the medicine's side effects and what to watch for.